Airway hyperresponsiveness, late allergic response, and eosinophilia are reversed with mycobacterial antigens in ovalbumin-presensitized mice

Michael T. Hopfenspirger, Devendra K. Agrawal

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

Pretreatment with mycobacterial Ags has been shown to be effective n preventing allergic airway inflammation from occurring in a mouse model. Because most asthmatics are treated after the development of asthma, it is crucial to determine whether mycobacterial Ags can reverse established allergic airway inflammation in the presensitized state. Our hypothesis, based upon our previous findings, is that mycobacteria treatment in presensitized mice will suppress the allergic airway inflammation with associated clinical correlates of established asthma, with the noted exception of factors associated with the early allergic response (EAR). BALB/c mice sensitized and challenged with OVA were evaluated for pulmonary functions during both the EAR and late allergic response, and airway hyperresponsiveness to methacholine. Following this, sensitized mice were randomized and treated with placebo or a single dose (1 × 105 CFUs) of bacillus Calmette-Guérin (BCG) or Mycobacterium vaccae via nasal or peritoneal injection. One week later, the mice were rechallenged with OVA and methacholine, followed by bronchoalveolar lavage (BAL) and tissue collection. Mice treated with intranasal BCG were most significantly protected from the late allergic response (p <0.02), airway hypersensitivity (p <0.001) and hyperreactivity (p <0.05) to methacholine, BAL (p <0.05) and peribronchial (p <0.01) eosinophilia, and BAL fluid IL-5 levels (p <0.01) as compared with vehicle-treated, sensitized controls. Intranasal M. vaccae treatment was less effective, suppressing airway hypersensitivity (p <0.01) and BAL eosinophilia (p <0.05). No changes were observed in the EAR, BAL fluid IL-4 levels, or serum total and Ag-specific IgE. These data suggest that mycobacterial Ags (BCG≫M. vaccae) are effective in attenuating allergic airway inflammation and associated changes in pulmonary functions in an allergen-presensitized state.

Original languageEnglish
Pages (from-to)2516-2522
Number of pages7
JournalJournal of Immunology
Volume168
Issue number5
StatePublished - Mar 1 2002

Fingerprint

Ovalbumin
Eosinophilia
Antigens
Methacholine Chloride
Bronchoalveolar Lavage
Inflammation
Bronchoalveolar Lavage Fluid
Mycobacterium
Bacillus
Hypersensitivity
Asthma
Lung
Interleukin-5
Nose
Interleukin-4
Allergens
Immunoglobulin E
Placebos
Injections
Therapeutics

All Science Journal Classification (ASJC) codes

  • Immunology

Cite this

Airway hyperresponsiveness, late allergic response, and eosinophilia are reversed with mycobacterial antigens in ovalbumin-presensitized mice. / Hopfenspirger, Michael T.; Agrawal, Devendra K.

In: Journal of Immunology, Vol. 168, No. 5, 01.03.2002, p. 2516-2522.

Research output: Contribution to journalArticle

@article{1e2e1a633e894d67aba6dc14b6962372,
title = "Airway hyperresponsiveness, late allergic response, and eosinophilia are reversed with mycobacterial antigens in ovalbumin-presensitized mice",
abstract = "Pretreatment with mycobacterial Ags has been shown to be effective n preventing allergic airway inflammation from occurring in a mouse model. Because most asthmatics are treated after the development of asthma, it is crucial to determine whether mycobacterial Ags can reverse established allergic airway inflammation in the presensitized state. Our hypothesis, based upon our previous findings, is that mycobacteria treatment in presensitized mice will suppress the allergic airway inflammation with associated clinical correlates of established asthma, with the noted exception of factors associated with the early allergic response (EAR). BALB/c mice sensitized and challenged with OVA were evaluated for pulmonary functions during both the EAR and late allergic response, and airway hyperresponsiveness to methacholine. Following this, sensitized mice were randomized and treated with placebo or a single dose (1 × 105 CFUs) of bacillus Calmette-Gu{\'e}rin (BCG) or Mycobacterium vaccae via nasal or peritoneal injection. One week later, the mice were rechallenged with OVA and methacholine, followed by bronchoalveolar lavage (BAL) and tissue collection. Mice treated with intranasal BCG were most significantly protected from the late allergic response (p <0.02), airway hypersensitivity (p <0.001) and hyperreactivity (p <0.05) to methacholine, BAL (p <0.05) and peribronchial (p <0.01) eosinophilia, and BAL fluid IL-5 levels (p <0.01) as compared with vehicle-treated, sensitized controls. Intranasal M. vaccae treatment was less effective, suppressing airway hypersensitivity (p <0.01) and BAL eosinophilia (p <0.05). No changes were observed in the EAR, BAL fluid IL-4 levels, or serum total and Ag-specific IgE. These data suggest that mycobacterial Ags (BCG≫M. vaccae) are effective in attenuating allergic airway inflammation and associated changes in pulmonary functions in an allergen-presensitized state.",
author = "Hopfenspirger, {Michael T.} and Agrawal, {Devendra K.}",
year = "2002",
month = "3",
day = "1",
language = "English",
volume = "168",
pages = "2516--2522",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "5",

}

TY - JOUR

T1 - Airway hyperresponsiveness, late allergic response, and eosinophilia are reversed with mycobacterial antigens in ovalbumin-presensitized mice

AU - Hopfenspirger, Michael T.

AU - Agrawal, Devendra K.

PY - 2002/3/1

Y1 - 2002/3/1

N2 - Pretreatment with mycobacterial Ags has been shown to be effective n preventing allergic airway inflammation from occurring in a mouse model. Because most asthmatics are treated after the development of asthma, it is crucial to determine whether mycobacterial Ags can reverse established allergic airway inflammation in the presensitized state. Our hypothesis, based upon our previous findings, is that mycobacteria treatment in presensitized mice will suppress the allergic airway inflammation with associated clinical correlates of established asthma, with the noted exception of factors associated with the early allergic response (EAR). BALB/c mice sensitized and challenged with OVA were evaluated for pulmonary functions during both the EAR and late allergic response, and airway hyperresponsiveness to methacholine. Following this, sensitized mice were randomized and treated with placebo or a single dose (1 × 105 CFUs) of bacillus Calmette-Guérin (BCG) or Mycobacterium vaccae via nasal or peritoneal injection. One week later, the mice were rechallenged with OVA and methacholine, followed by bronchoalveolar lavage (BAL) and tissue collection. Mice treated with intranasal BCG were most significantly protected from the late allergic response (p <0.02), airway hypersensitivity (p <0.001) and hyperreactivity (p <0.05) to methacholine, BAL (p <0.05) and peribronchial (p <0.01) eosinophilia, and BAL fluid IL-5 levels (p <0.01) as compared with vehicle-treated, sensitized controls. Intranasal M. vaccae treatment was less effective, suppressing airway hypersensitivity (p <0.01) and BAL eosinophilia (p <0.05). No changes were observed in the EAR, BAL fluid IL-4 levels, or serum total and Ag-specific IgE. These data suggest that mycobacterial Ags (BCG≫M. vaccae) are effective in attenuating allergic airway inflammation and associated changes in pulmonary functions in an allergen-presensitized state.

AB - Pretreatment with mycobacterial Ags has been shown to be effective n preventing allergic airway inflammation from occurring in a mouse model. Because most asthmatics are treated after the development of asthma, it is crucial to determine whether mycobacterial Ags can reverse established allergic airway inflammation in the presensitized state. Our hypothesis, based upon our previous findings, is that mycobacteria treatment in presensitized mice will suppress the allergic airway inflammation with associated clinical correlates of established asthma, with the noted exception of factors associated with the early allergic response (EAR). BALB/c mice sensitized and challenged with OVA were evaluated for pulmonary functions during both the EAR and late allergic response, and airway hyperresponsiveness to methacholine. Following this, sensitized mice were randomized and treated with placebo or a single dose (1 × 105 CFUs) of bacillus Calmette-Guérin (BCG) or Mycobacterium vaccae via nasal or peritoneal injection. One week later, the mice were rechallenged with OVA and methacholine, followed by bronchoalveolar lavage (BAL) and tissue collection. Mice treated with intranasal BCG were most significantly protected from the late allergic response (p <0.02), airway hypersensitivity (p <0.001) and hyperreactivity (p <0.05) to methacholine, BAL (p <0.05) and peribronchial (p <0.01) eosinophilia, and BAL fluid IL-5 levels (p <0.01) as compared with vehicle-treated, sensitized controls. Intranasal M. vaccae treatment was less effective, suppressing airway hypersensitivity (p <0.01) and BAL eosinophilia (p <0.05). No changes were observed in the EAR, BAL fluid IL-4 levels, or serum total and Ag-specific IgE. These data suggest that mycobacterial Ags (BCG≫M. vaccae) are effective in attenuating allergic airway inflammation and associated changes in pulmonary functions in an allergen-presensitized state.

UR - http://www.scopus.com/inward/record.url?scp=0036498801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036498801&partnerID=8YFLogxK

M3 - Article

VL - 168

SP - 2516

EP - 2522

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 5

ER -